Show simple item record

dc.contributor.authorBerthon, Cen_US
dc.contributor.authorRaffoux, Een_US
dc.contributor.authorThomas, Xen_US
dc.contributor.authorVey, Nen_US
dc.contributor.authorGomez-Roca, Cen_US
dc.contributor.authorYee, Ken_US
dc.contributor.authorTaussig, DCen_US
dc.contributor.authorRezai, Ken_US
dc.contributor.authorRoumier, Cen_US
dc.contributor.authorHerait, Pen_US
dc.contributor.authorKahatt, Cen_US
dc.contributor.authorQuesnel, Ben_US
dc.contributor.authorMichallet, Men_US
dc.contributor.authorRecher, Cen_US
dc.contributor.authorLokiec, Fen_US
dc.contributor.authorPreudhomme, Cen_US
dc.contributor.authorDombret, Hen_US
dc.date.accessioned2020-02-24T09:56:38Z
dc.date.issued2016-04en_US
dc.identifier.citationThe Lancet. Haematology, 2016, 3 (4), pp. e186 - e195en_US
dc.identifier.issn2352-3026en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3514
dc.identifier.eissn2352-3026en_US
dc.identifier.doi10.1016/s2352-3026(15)00247-1en_US
dc.description.abstractBromodomain and extraterminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes. BET proteins bind acetylated histone tails via their bromodomain, bringing the elongation complex to the promoter region. OTX015 (MK-8628) specifically binds to BRD2, BRD3, and BRD4, preventing BET proteins from binding to the chromatin, thus inhibiting gene transcription. OTX015 inhibits proliferation in many haematological malignancy cell lines and patient cells, in vitro and in vivo. We aimed to establish the recommended dose of OTX015 in patients with haematological malignancies. We report the results of patients with acute leukaemia (leukaemia cohort).In this dose-escalation, phase 1 study we recruited patients from seven university hospital centres (in France [five], UK [one], and Canada [one]). Adults with acute leukaemia who had failed or had a contraindication to standard therapies were eligible to participate. OTX015 was given orally at increasing doses from 10 mg/day to 160 mg/day (14 of 21 days), using a conventional 3 + 3 design. In this open-label trial, OTX015 was initially administered once a day, with allowance for exploration of other schedules. The primary endpoint was dose-limiting toxicity (DLT), assessed during the first treatment cycle (21 days). The study is ongoing and is registered with ClinicalTrials.gov, NCT01713582.Between Jan 18, 2013, and Sept 9, 2014, 41 patients, 36 with acute myeloid leukaemia, a median age of 70 years (IQR 60-75) and two lines of previous therapy, were recruited and treated across six dose levels of OTX015. No DLT was recorded until 160 mg/day, when one patient had grade 3 diarrhoea and another had grade 3 fatigue. However, concomitant grade 1-2 non-DLT toxic effects (ie, gastrointestinal, fatigue, or cutaneous) from 120 mg doses hampered patient compliance and 80 mg once a day was judged the recommended dose with a 14 days on, 7 days off schedule. Common toxic effects for all OTX015 doses were fatigue (including grade 3 in three patients) and bilirubin concentration increases (including grade 3-4 in two patients). OTX015 plasma exposure increased proportionally up to 120 mg/day with trough concentrations in the in-vitro active range from 80 mg/day (274 nmol/L). Three patients (receiving 40 mg/day, 80 mg/day, and 160 mg/day) achieved complete remission or complete remission with incomplete recovery of platelets lasting 2-5 months, and two additional patients had partial blast clearance. No predictive biomarkers for response have been identified so far.The once-daily recommended dose for oral, single agent oral OTX015 use in patients with acute leukaemia for further phase 2 studies is 80 mg on a 14 days on, 7 days off schedule.Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.en_US
dc.formatPrint-Electronicen_US
dc.format.extente186 - e195en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleBromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.en_US
dc.typeJournal Article
dcterms.dateAccepted2015-11-04en_US
rioxxterms.versionofrecord10.1016/s2352-3026(15)00247-1en_US
rioxxterms.licenseref.startdate2016-04en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfThe Lancet. Haematologyen_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia/Acute Leukaemia (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume3en_US
pubs.embargo.termsNot knownen_US
icr.researchteamAcute Leukaemiaen_US
dc.contributor.icrauthorTaussig, Daviden_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record